ImmunityBio (IBRX) Q3 2025 earnings summary

Executive summary

• Achieved $32.1 million in Q3 2025 product revenue, a 434% year-over-year increase, driven by ANKTIVA sales following FDA approval and commercial launch.

• Total revenue and other income for Q3 2025 reached $33.7 million, up from $26.4 million in Q2 2025.

• Net loss for Q3 2025 was $67.3 million, improved from $85.8 million in Q3 2024, with a year-to-date net loss of $289.5 million.

• Cash, cash equivalents, and marketable securities totaled $257.8 million as of September 30, 2025, up from $149.8 million at year-end 2024.

• Significant clinical progress in glioblastoma, non-small cell lung cancer, and non-Hodgkin lymphoma, with new trials initiated and positive early results reported.

Financial highlights

• Product revenue for the nine months ended September 30, 2025 was $74.7 million, up from $0.3 million in the prior year period.

• Gross margin remains high due to pre-launch inventory costs being expensed prior to regulatory approval; Q3 2025 cost of sales was $177,000 on $31.8 million product revenue.

• Research and development expenses were $154.7 million year-to-date, flat compared to the prior year.

• Selling, general and administrative expenses decreased 12% year-over-year to $111.3 million, reflecting lower legal and consulting costs.

• Interest expense related to the revenue interest liability increased to $39.2 million year-to-date.

Outlook and guidance

• Management expects continued revenue growth from ANKTIVA, but notes that it will take time to offset operating expenses.

• Ongoing expansion of ANKTIVA's reach, with optimism for broader adoption in bladder cancer and other indications.

• Awaiting NCCN decision on guideline expansion for BCG-unresponsive NMIBC to include papillary-only disease.

• Substantial additional funding will be needed to support ongoing operations, commercialization, and clinical development.

• Existing cash, marketable securities, and anticipated product sales are expected to fund operations for at least the next 12 months, with additional equity or debt financing likely required.